Bayer Healthcare Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Kevin Nash

Karl-Heinz Schlemmer

Mary F Fitzgerald

Volkhart Min-Jian Li

Ulrich Rosentreter

Heike Gielen-Haertwig

Swen Allerheiligen

Lars Bärfacker

Leila Telan

Barbara Albrecht

Dirk Meurer

Jörg Keldenich

Bernd Riedl

Helmut Haning

Graham Sturton

Rolf Henning

Jörg Keldenieh

Philip J Gardiner

Günter Benz

Lorenz Mayr

The invention relates to 4-cyanophenyl, 2-sulfanyl, 1-phenyl pyrimidine derivatives, processes for their preparation, and pharmaceutical compositions of the same. Compounds and compositions of the invention are useful in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.

I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use

The invention relates to novel dihydropyridine derivatives, of Formula (I) processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. 

Dihydropyridine derivatives for use as human neutrophil elastase inhibitors

The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases.

Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes

The invention relates to novel 1-Phenyl-3,4-dihydropyrimidin-2(1H)-one derivatives having the formula 

1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use

The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

Dihydropyridinone derivatives

The invention relates to novel 1,4-dihydro-1,4-diphenylpyridine derivatives of formula (I) wherein the variable groups are as defined in the text and claims. Processes for their preparation, pharmaceutical compositions containing them, and methods of treatment of inflammatory processes, expecially chronic obstructive pulmonary diseases, using them are also disclosed and claimed.

1,4-dihydro-1,4-diphenylpyridine derivatives

Novel 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives, use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloprotease Inhibitors for the Treatment of Respiratory Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (I) (T)A&#x2014;B&#x2014;D&#x2014;E&#x2014;COH wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group, x is 0, 1, or 2; the group D represents (a), (b), (c), or (d); the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases

Growing community of inventors

Herts, United Kingdom

Kevin Nash